Structure-Based Methods for the Prediction of the Dominant P450 Enzyme in Human Drug Biotransformation: Consideration of CYP3A4, CYP2C9, CYP2D6

Metabolic drug–drug interactions are receiving more and more attention from the in silico community. Early prediction of such interactions would not only improve drug safety but also contribute to make drug design more predictable and rational. The aim of this study was to build a simple and interpretable model for the determination of the P450 enzyme predominantly responsible for a drug's metabolism. The P450 enzymes taken into consideration were CYP3A4, CYP2D6 and CYP2C9. Physico-chemical descriptors and structural descriptors for 96 currently marketed drugs were submitted to statistical analysis using the formal inference-based recursive modelling (FIRM) method, a form of recursive partitioning. Generally accepted knowledge on metabolism by these enzymes was also used to construct a hierarchical decision tree. Robust methods of variable selection using recursive partitioning were utilised. The descriptive ability of the resulting hierarchical model is very satisfactory, with 94% of the compounds correctly classified.

[1]  P. Anzenbacher,et al.  Cytochromes P450 and metabolism of xenobiotics , 2001, Cellular and Molecular Life Sciences CMLS.

[2]  S. Ekins,et al.  Application of in silico approaches to predicting drug--drug interactions. , 2001, Journal of pharmacological and toxicological methods.

[3]  Oleg A. Raevsky Hydrogen Bond Strength Estimation by Means of the HYBOT Program Package , 2007 .

[4]  B G Woodcock,et al.  Systematic screening for pharmacokinetic interactions during drug development. , 1996, International journal of clinical pharmacology and therapeutics.

[5]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .

[6]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[7]  D. Lewis,et al.  On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. , 2000, Biochemical pharmacology.

[8]  Elizabeth Landrum Michalets,et al.  Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.

[9]  T. Shimada,et al.  Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. , 1991, Chemical research in toxicology.

[10]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.

[11]  D A Smith,et al.  Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[12]  Maurice Dickins,et al.  Substrate SARs in human P450s. , 2002, Drug discovery today.

[13]  Steven L. Dixon,et al.  Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition , 2003, J. Chem. Inf. Comput. Sci..

[14]  Danielson Pb,et al.  The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002 .

[15]  P. Danielson,et al.  The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002, Current drug metabolism.

[16]  A. Tropsha,et al.  Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. , 2003, Journal of medicinal chemistry.

[17]  Sean Ekins,et al.  Pharmacophore modeling of cytochromes P450. , 2002, Advanced drug delivery reviews.

[18]  Dennis A. Smith,et al.  Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates , 1997 .